Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tissue registration

This article was originally published in The Gray Sheet

Executive Summary

Human cellular or tissue products manufacturers regulated under 21 CFR 1270 must register and list products by May unless President Bush decides to include the reg in his regulatory review plan, FDA says in Feb. 13 Q&As on the agency's Tissue Action Plan (21 CFR 1271), which is comprised of three regulations. On Jan. 18, the agency signed off on the registration rule (1"The Gray Sheet" Jan. 22, p. 10); FDA will rescind 21 CFR 1270 once it finalizes two remaining rules covering donor suitability and good tissue practice. Manufacturers of products not regulated under 21 CFR 1270; device manufacturers must register and list with revised Form 3356 by Jan. 21, 2003

You may also be interested in...



FDA Tissue Registration Rule Clarifies Classification Of Combination Devices

Manufacturers of combination devices incorporating human cells or tissues will have until Jan. 19, 2003 to register with FDA, according to a final rule released by the agency Jan. 18.

Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker

Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line

Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel